John Taylor, new Idera Pharmaceuticals CEO
September 29, 2022 07:10 AM EDT
Deals

As lead drug flopped and Ab­b­Vie col­lab dis­solved, can­cer biotech re­sorts to buy­ing rare dis­ease com­pa­ny

Amber Tong

Ever since dis­ap­point­ing late-stage da­ta on its can­cer drug tanked Idera Phar­ma­ceu­ti­cals’ stock last year (un­helped by an ill-fat­ed col­lab­o­ra­tion with Ab­b­Vie), ex­ecs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times